VICTOZA

This brand name is authorized in United States. It is also authorized in Austria, Brazil, Canada, Croatia, Cyprus, Estonia, Finland, France, Hong Kong SAR China, Ireland, Israel, Italy, Japan, Lithuania, Netherlands, New Zealand, Poland, Romania, Singapore, South Africa, Spain, Tunisia, Turkey, UK.

Active ingredients

The drug VICTOZA contains one active pharmaceutical ingredient (API):

1	Liraglutide UNII 839I73S42A - LIRAGLUTIDE
	Liraglutide is a GLP-1 analogue with 97% sequence homology to human GLP-1 that binds to and activates the GLP-1 receptor. The GLP-1 receptor is the target for native GLP-1, an endogenous incretin hormone that potentiates glucose-dependent insulin secretion from the pancreatic beta cells. Unlike native GLP-1, liraglutide has a pharmacokinetic and pharmacodynamic profile in humans suitable for once daily administration.
	Read more about Liraglutide

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
VICTOZA Solution for injection	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
A10BJ02	Liraglutide	A Alimentary tract and metabolism → A10 Drugs used in diabetes → A10B Blood glucose lowering drugs, excl. insulins → A10BJ Glucagon-like peptide-1 (GLP-1) analogues
Discover more medicines within A10BJ02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
BR	Câmara de Regulação do Mercado de Medicamentos	526602302159211
CA	Health Products and Food Branch	02351064
EE	Ravimiamet	1426834, 1426845, 1426856, 1426867, 1426878
ES	Centro de información online de medicamentos de la AEMPS	09529002
FI	Lääkealan turvallisuus- ja kehittämiskeskus	050365, 080629
FR	Base de données publique des médicaments	62645506
GB	Medicines & Healthcare Products Regulatory Agency	158587, 158590, 369047, 377090
HK	Department of Health Drug Office	61180
IE	Health Products Regulatory Authority	13221, 47980, 47981, 47989
IL	מִשְׂרַד הַבְּרִיאוּת	6292
IT	Agenzia del Farmaco	039365010, 039365022
JP	医薬品医療機器総合機構	2499410G1021
LT	Valstybinė vaistų kontrolės tarnyba	1050600, 1050601, 1050602, 1050603, 1050604
NL	Z-Index G-Standaard, PRK	91634
NZ	Medicines and Medical Devices Safety Authority	13616
PL	Rejestru Produktów Leczniczych	100213307
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W54586001, W54586002, W54586003, W54586004, W54586005
SG	Health Sciences Authority	13905P
TN	Direction de la Pharmacie et du Médicament	5993111
TR	İlaç ve Tıbbi Cihaz Kurumu	8699676950881, 8699676950928, 8699676950935, 8699676950942, 8699676950959
US	FDA, National Drug Code	0169-4060, 50090-4503
ZA	Health Products Regulatory Authority	43/21.13/0781